Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $31.67 Consensus Target Price from Analysts
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […]
More Stories
Head to Head Analysis: U Power (NASDAQ:UCAR) & Dorman Products (NASDAQ:DORM)
U Power (NASDAQ:UCAR – Get Free Report) and Dorman Products (NASDAQ:DORM – Get Free Report) are both auto/tires/trucks companies, but...
Village Farms International, Inc. (TSE:VFF) Director Buys C$12,552.30 in Stock
Village Farms International, Inc. (TSE:VFF – Get Free Report) Director Stephen Ruffini bought 10,000 shares of the firm’s stock in...
Jaguar Mining Inc. (TSE:JAG) Senior Officer Sells C$11,280.00 in Stock
Jaguar Mining Inc. (TSE:JAG – Get Free Report) Senior Officer Jonathan Victor Hill sold 2,000 shares of the firm’s stock...
Able View Global Inc. (NASDAQ:ABLV) Sees Significant Decline in Short Interest
Able View Global Inc. (NASDAQ:ABLV – Get Free Report) saw a significant decline in short interest in the month of...
Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $33.67
enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven analysts...
Brokerages Set Rubrik, Inc. (NYSE:RBRK) PT at $44.69
Rubrik, Inc. (NYSE:RBRK – Get Free Report) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are...